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A B S T R A C T
Introduction: Current evidence on the association between COVID-19 and dementia is sparse. This study aims to
investigate the associations between COVID-19 caseload and the burden of dementia.
Methods: We gathered data regarding burden of dementia (disability-adjusted life years [DALYs] per 100,000),
life expectancy, and healthy life expectancy (HALE) from the Global Burden of Disease (GBD) 2017 study. We
obtained COVID-19 data from Our World in Data database. We analyzed the association of COVID-19 cases and
deaths with the burden of dementia using Spearman's rank correlation coefficient.
Results: Globally, we found significant positive (p < .001) correlations between life expectancy (r = 0.60),
HALE (r = 0.58), and dementia DALYs (r = 0.46) with COVID-19 caseloads. Likewise, we found similar cor-
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relations between life expectancy (r = 0.60), HALE (r = 0.58) and dementia DALYs (r = 0.54) with COVID-19
mortality.
Conclusion: Health policymakers should clarify a targeted model of disease surveillance in order to reduce the
dual burden of dementia and COVID-19.
1. Introduction
With the emergence of COVID-19 pandemic, it is crucial to identify
those at increased risk of infection and death. The worldwide pre-
valence of dementia has increased dramatically over the past three
decades, mainly due to an ageing population [1]. Patients with de-
mentia are among the most vulnerable populations due to ageing,
frailty [2], chronic immune dysregulation [3] and comorbidity of other
chronic diseases, particularly vascular disorders [4]. Individuals with
dementia are faced with a “double burden”, as the pandemic exacer-
bates both their vulnerability due to increased morbidity and mortality
and breakdown of their social supports and access to their healthcare
system due to lockdown and social distancing measures [5].
Epidemiological evidence has shown a significant association be-
tween communicable diseases and dementia [6–9]. Those with de-
mentia had poor clinical outcomes and increased hospitalization rate
after respiratory syncytial virus disease [6], severe acute respiratory
syndrome (SARS) coronavirus (SARS-CoV) [7], and influenza A infec-
tions [8–10]. Recent evidence showed that there is a high prevalence of
dementia among COVID-19 patients [11,12]. In addition, case fatality
of COVID-19 is significantly higher in the elderly with dementia
[13,14]. However, the nature of this association has not yet been clearly
evaluated on a global perspective and it may take several months to
gather enough epidemiological and clinical data to address this issue.
In a recent study, using the Global Burden of Diseases, Injuries, and
Risk Factors Study (GBD) 2017 database [15], we observed a significant
yet weak correlation between all non-communicable diseases, including
ischemic stroke and ischemic heart diseases with COVID-19 confirmed
cases and deaths. Furthermore, life expectancy and healthy life ex-
pectancy (HALE) had independent positive associations with COVID-19
caseload and mortality.
The purpose of this study is to assess the association between the
national and global burden of dementia and COVID-19 confirmed cases
and death. We will also provide a brief review of the literature re-
garding the association between COVID-19 and dementia and sum-
marize available recommendations to reduce the dual burden of de-
mentia and COVID-19.
2. Materials and methods
We gathered data regarding regional and national mortality of
Alzheimer's disease and related dementias (later regarded as dementia)
from the GBD 2017 study database [16]. We used disability-adjusted
life years (DALYs) per 100,000 (with 95% uncertainty intervals [UIs])
to measure the burden of dementia. Using the GBD 2017 database, we
also collected data regarding national and regional HALE and life ex-
pectancy with their 95% UIs. Data regarding the COVID-19 confirmed
cases, and deaths per million population, and the percentage of popu-
lation aged ≥65 and aged ≥70 years was retrieved using Our World in
Data. We categorized all countries into a) seven GBD super regions,
including 1. South Asia, 2. Southeast Asia, East Asia & Oceania, 3.
Central Europe, Eastern Europe & Central Asia, 4. North Africa &
Middle East, 5. Sub-Saharan Africa, 6. Latin America & Caribbean, and
7. high-income; b) world Bank income levels, including (1. Low-income
countries, 2. lower middle-income countries, 3. upper middle-income
countries, and 4. high-income countries [17].
We calculated COVID-19 confirmed cases and deaths per million
population with their 95% confidence intervals (CIs) by each region.
We used Spearman's rank correlation coefficient with Bonferroni
correction to analyse the association of COVID-19 caseload and deaths
with the burden and mortality of dementia. We also assessed correla-
tions between national and global life expectancy and HALE with
COVID-19 cases and death using Spearman's rank correlation coeffi-
cient. We used STATA software (version 13) for all statistical analysis.
Data reported in this paper are publicly available with no personal
identifiers.
3. Results
Table 1 summarizes regional and national data regarding COVID-19
confirmed cases, deaths, and the burden of dementia. According to the
GBD 2017 data, 4% and 1% of mortality and burden of all disease,
respectively, were attributed to dementia. The highest rate of dementia
DALYs per 100,000 was observed in the high-income region (955.65),
followed by Central Europe, Eastern Europe, and Central Asia (670.18),
and Southeast Asia, East, East Asia, and Oceania (438.06) (Table 1.A).
The greatest rate of dementia deaths were also observed in the high-
income GBD region (93.74), followed by Central Europe, Eastern
Europe, and Central Asia (56.12), and Latin America and the Caribbean
(30.27) (Table 1.A). Likewise, using the World Bank classification, we
found higher dementia DALYs and deaths in high-income countries
compared to low- and middle-income countries (Table 1.B). In 2017,
HALE were significantly higher in high-income countries as compared
to low-income countries (69.4 [66.15 to 72.18] vs. 55.66 [53.17 to
57.97]). We found similar findings regarding life expectancy. Likewise,
the highest percentage of the population aged ≥65 and aged ≥70 years
was seen in the high-income region and high-income countries.
As of June 10, 2020, the highest number of COVID-19 confirmed
cases (3453.27) and deaths (269.23) were reported in high-income
regions (Table 1.A). Globally, we found significant moderate positive
correlations between life expectancy (r = 0.60, p < .001), HALE
(r = 0.58, P < .001), and dementia DALYs (r = 0.46, p < .001) with
COVID-19 caseloads (Fig. 1.A). Likewise, there were significant corre-
lations between COVID-19 mortality with life expectancy (r = 0.60;
p < .001) HALE (r = 0.58; P < .001), and dementia DALYs
(r = 0.54; P < .001) (Fig. 1.B).
4. Discussion
The results of this study have major public health implications.
Using available GBD 2017 data regarding dementia and COVID-19 in
185 countries, we found a significant correlation between the burden of
dementia and COVID-19 cases and deaths. There were also positive
correlations between life expectancy and HALE with COVID-19 cases
and deaths. To the best of our knowledge, this is the first study re-
porting a correlation between COVID-19 and dementia on a global
scale.
The world is facing an ageing population [18]. Among age-related
health conditions, dementia is one of the most burdensome in the world
with significant health and social well-being implications [19]. In 2016,
about 43.8 million people were reported to be living with dementia [1]
with huge social and personal costs [20]. Older adults with underlying
health issues are known to be at increased risk of severe COVID-19 and
mortality [3]. Therefore, access to accurate data regarding dementia
and ageing population is a research priority worldwide, particularly in
the era of COVID-19 pandemic.
We found that life expectancy and HALE had significant correlations
with COVID-19 case numbers and deaths. As reported earlier [21,22],
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HALE and life expectancy were higher in high-income countries than
those of low- and middle-income countries. In addition, the highest
percentage of citizens aged ≥65 and ≥ 70 years were seen in high-
income countries followed by upper middle-income countries. These
findings may partially explain a higher rate and rapid spread of COVID-
19 pandemic in many high-income countries [23,24]. Older adults have
slower and less efficient immune responses, making them more vul-
nerable to COVID-19 consequences [3]. Additionally, a substantial
number of COVID-19 cases and deaths occured in the elderly residing in
long-term care facilities and assisted living [13,25,26] often available in
high-income countries. Data from the National Survey of Residential
Care Facilities in the United States showed that seven out of ten in-
dividuals in assisted living had some cognitive impairment, ranging
from mild (29%) to severe cognitive impairment (19%) [27]. A com-
bination of ageing, frailty and comorbidities make these individuals
more susceptible to COVID-19 severe consequences.
Our results also suggest a significant correlation between dementia
DALYs and COVID-19 cases. The rate of dementia in hospitalized cases
COVID-19 varied from 6.8% [11] to 13.1% [12]. A higher rate of
COVID-19 among patients with dementia might be partially explained
by problems with appropriate safeguard, self-quarantine procedures,
less adherence to social distancing, and living in long-term care facil-
ities [28].
Dementia is a strong predictor of COVID-19 mortality [29]. In our
study, we found a significant correlation between dementia DALYs and
COVID-19 mortality. In the UK Biobank study, a large community-
based cohort (n = 274,356 participants aged 65+, including 448
hospitalized COVID-19 patients) pre-existing dementia was associated
with COVID-19 severity (odds ratio = 3.07, 95% CI: 1.71 to 5.50) [29]
and increased mortality rate. Likewise, among 627 Italian patients with
COVID-19, the mortality rate increased significantly (p < .001) in
those with dementia (62.2%) as compared to those without (26.2%).
Among 20,133 cases with COVID-19 admitted in 208 hospitals in the
UK, chronic non-communicable diseases including dementia increased
hospital mortality [30]. Case fatality rate in long-term care facilities is
high, ranging from 20% [14] to 33.7% [13]. Increased risk of adverse
outcomes and patient safety in hospitalized cases with dementia has
been a challenging condition even prior ot COVID-19 pandemic [31]. A
high mortality rate of COVID-19 among demented patients could be
partially explained by ageing and chronic comorbidities, particularly
cardio or cerebr-vascular diseases [32,33]. In addition, using the UK
Biobank databasebase and after adjusting for pre-existing dementia,
cardiovascular diseases, and type-2 diabetes, Kuo et al. showed that the
ApoE e4e4 allele is associated with severe COVID-19 infection [34].
There is no silver bullet solution to reduce the dual burden of de-
mentia and COVID-19. However, it is still possible to reduce the burden
of COVID-19 among patients with dementia and their caregivers [5].
Prevention of COVID-9 in the elderly, particularly those with dementia,
or residents of long-term care facilities requires a coordinated approach
with a close collaboration between family members and health pro-
fessionals. Strict environmental clearance, hand hygiene, safe distance
between residents to reduce droplet contamination can prevent COVID-
19 spread [35].
Those with cognitive impairment may need additional support in
order to adequately practice infection control procedures during the
COVID-19 era. These procedures are also crucial for caregivers of pa-
tients with dementia who may be at risk of COVID-19 [13]. Active
surveillance/testing of patients, caregivers, and staff in long-term care
facilities, are highly recommended to reduce the chance of COVID-19.
Older adults with COVID-19 may be afebrile with atypical symptoms
[36]. In addition, patients with dementia who develop COVID-19 may
present with non-respiratory symptoms such as delirium (particularly
the hypoactive form) or isolated functional decline in the absence of
any obvious physical symptoms [36]. These atypical presentations of
COVID-19 may reduce early recognition of disease, increase COVID-19
spread and mortality among patients and caregivers. Moreover, fear of
presenting to hospitals and medical facilities for patients and their
caregiver may increase the rate of spread and mortality of COVID-19
among the elderly. Hospital administration and public health officials
should encourage patients/caregivers to seek medical attention, re-
assure them that hospitals are safe and they will ensure patient safety
while in hospital.
Compared to the pre-COVID-19 era, residents of long-term care fa-
cilities and patients with dementia should have a higher frequency of
vital signs monitoring and observations for any changes in clinical
status [36]. Long-term care facilities and caregivers should implement
Fig. 1. A. Correlation between Alzheimer's disease and other dementias DALYs rate and: A. Total number of COVID-19 cases per million. B. Total number of COVID-
19 deaths per million.
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frequent check ups using simple questionnaires or checklists regarding
activity level, potential exposure, change in appetite, generalized
weakness, change in temperature or pulse rate to identify suspected
cases with COVID-19. These screening approaches may be linked to
national and local public health screening tools (if available) to provide
an active surveillance model for the elderly. Furthermore, staff that
work in residential care facilities are often poorly trained, unregulated
and overworked [37], which creates further risk for COVID-19 trans-
mission. Thus, there is a need to dedicate funds and regulate training
for staff at residential and long term care facilities.
While social distancing and safeguard procedures are still the most
effective approaches to prevent COVID-19 infection, these approaches
should not endanger the safety of patients with dementia [38]. Older
individuals with cognitive impairment are among the most vulnerable
persons and often need help in their activities of daily living, medica-
tion adherence, social and leisure activities [39]. Due to the COVID-19
pandemic, family, friends, or professional caregivers may self isolate
themselves due to fear of infection, and may refrain from visiting due to
changes in their lifestyle due to COVID-19. The lack of adequate and
previously established formal and informal support in these patients
may further endanger their lives due to risk of falls [40], aspiration
pneumonia [41] and even suicide [42]. In addition, lack of in-person
support, face-to-face visits with friends and family members, group
activities, and exercise with peers may increase the sense of loneliness
[43], isolation and depression particularly in the elderly [44]. These
conditions may increase the chance of delirium [45] and aggressive
behaviors leading to self injuries [46].
Whenever possible, individuals with dementia should be en-
couraged to participate in their daily routine, remain physically active,
maintain proper sleep hygiene, and engage in leisure activities [47].
Telehealth home support during COVID-19 may assist those with milder
cognitive impairment due to its recreational component and intellectual
activity [47]. For individuals with milder forms of cognitive impair-
ment, activities such as relaxation, meditation, group exercise, and
social interactions using cross-platform mobile applications and video-
call technology may prevent a sense of loneliness and maintain mental
and physical health [48]. However, barriers to technology use including
fear and lack of familiarity, in addition to hearing/vision loss may re-
duce the effectiveness of these approaches.
This study has some limitations. The data for COVID-19 is dynamic
and some of the most readily accessible data is publicly available ag-
gregate population level data. Given the ecological design of the study,
the results need to be interpreted as correlational and not causal, due to
the potential for ecological fallacy [49]. There is an observed difference
between the number of COVID-19 cases and deaths reported in low- and
middle-income countries vs. high-income countries. This under-re-
porting may be due to decreased capacity for testing and active sur-
veillance in the low and middle-income countries. Another limitation is
the fact that we did not adjust for potential confounders that may be
contributing to the correlation. There is a concern that confounding
may further distort or create misleading results when comparing
COVID-19 rates in rich versus poorer countries [50]. Adjusting for
multiple potential confounders may create instability in adjusted
models. The major strength of our study is based on combining multiple
available databases regarding COVID-19 pandemic and GBD 2017
study. This information provides the opportunity to assess the corre-
lations between dementia and COVID-19 at a global scale to inform
policy makers, researchers, and clinicians about global differences in
dementia trends.
5. Conclusions
In the current study, we found significant correlations between
global and national burden of dementia and COVID-19 cases and death.
In this critical stage of the pandemic when countries are planning to
end their national lockdown and begin to open their borders, health
policy makers must have comprehensive plans to identify those at risk
(including older people) and reduce the chance of infection while
maintaining appropriate attention to medical and psychosocial well-
being. If a vaccination becomes available, such patients could also be
prioritized given their risk status.
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